{"links":{"feed":"https://www.erudio.com/reports/violette-nct03330847/feed.json","html":"https://www.erudio.com/reports/violette-nct03330847","json":"https://www.erudio.com/reports/violette-nct03330847.json","markdown":"https://www.erudio.com/reports/violette-nct03330847.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"violette-nct03330847"}},"request":"https://www.erudio.com/contact?report=violette-nct03330847"},"offer":{"cited_clinicians":2,"cited_commentary_sources":6,"verified_hcp_statements":24,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"verified_ids":{"included":"Every product, the free report included, comes with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself, inline on each person card under identifiers. Social accounts (X, Bluesky, LinkedIn) are not included. For checking attribution inside the organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians. Sample: https://www.erudio.com/report-sample.json","identity_verified_people":5},"for_sale":false,"one_off_usd":null,"not_for_sale":{"note":"This edition is below our minimum for clinicians and sources, so it is not for sale yet. Contact us if you are still interested. No order can be placed for it; a later edition that reaches the minimum is for sale at its normal price.","contact":"https://www.erudio.com/contact?report=violette-nct03330847","email":"hello@erudio.com"},"purchase":{"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=violette-nct03330847","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/violette-nct03330847","renewal":"Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_line":"Focused · 24 verified statements · 4 from 2 confirmed clinicians","size_rule":"Focused: 1–150 verified statements. Standard and Deep need 5 or more confirmed clinicians cited (role verified by the NPI registry or their own institution's staff page); otherwise a report is Focused.","updates_usd":null,"volume_discounts":{"applies_to":"Update plans (updates-3, updates-6, updates-12) only. Never a single edition (product edition), however many an account buys.","rule":"Volume discounts apply to update plans only: 15% off a plan when one account has update plans on 5 or more trials, 25% off from 10 or more. A single edition is never discounted, however many an account buys, and there are no other discounts.","tiers":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]}},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-11-19T17:38:25.022882Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":8,"no_commentary_found":1},"aspects":[{"claim_count":7,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":3,"title":"Primary endpoint: Progression-free Survival Per Stratum (BICR)"},{"claim_count":0,"coverage":"no_commentary_found","id":"T2","registry_field":"outcomesModule.primaryOutcomes[1]","source_count":0,"title":"Primary endpoint: Progression-free Survival Per Stratum (Sensitivity Analysis)"},{"claim_count":5,"coverage":"discussed","id":"T3","registry_field":"outcomesModule.secondaryOutcomes","source_count":2,"title":"Secondary endpoints"},{"claim_count":9,"coverage":"discussed","id":"T4","registry_field":"conditionsModule","source_count":3,"title":"Population and setting"},{"claim_count":10,"coverage":"discussed","id":"T5","registry_field":"armsInterventionsModule.armGroups","source_count":4,"title":"The comparison"},{"claim_count":5,"coverage":"discussed","id":"T6","registry_field":"outcomesModule","source_count":4,"title":"Safety and tolerability"},{"claim_count":5,"coverage":"discussed","id":"T7","registry_field":"designModule","source_count":5,"title":"Design and conduct"},{"claim_count":4,"coverage":"discussed","id":"A1","source_count":2,"title":"Questions about biomarker refinement and responder biology"},{"claim_count":2,"coverage":"discussed","id":"A2","source_count":2,"title":"Early ATR rationale and trial-launch expectations"}],"counts":{"cited_clinicians":2,"cited_clinicians_by_role":{"physician, Medical oncology":2},"cited_physicians":2,"cited_sources":7,"claims_by_expression_type":{"interpretation":5,"opinion":2,"primary_context":5,"question":2,"restatement":10},"claims_by_kind":{"publication_statement":6,"source_observation":18},"clinician_statements":4,"evidence_units":20,"findings":4,"organisational_accounts":3,"people_cited":6,"people_identity_verified":5,"people_total":6,"screened_sources":19,"verified_claims":24},"findings_index":[{"cited_clinicians":1,"id":"F1","structure":{"claims":12,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":7,"views":4},"limitations":3,"links":{"context":0,"support":14},"ma_question":true,"named_voices":2,"passages":9,"sources":5,"sources_by_kind":{"commentary":4,"publication":1}},"title":"VIOLETTE responses: a speaker highlights no significant PFS gain across strata","title_holders":{"cited_claim_ids":["claim-01e1f75f58bc77ad877a","claim-9bc7475b7e7fdd4ebc49","claim-fe7ffeeb70f8f72baefb"],"clinicians":false,"holders":1,"speakers":2,"view":"reading"},"evidence_line":"12 statements from 2 speakers in 5 sources","holder_line":"1 of the 2 named speakers in this finding holds this view"},{"cited_clinicians":1,"id":"F2","structure":{"claims":7,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":6,"views":1},"limitations":2,"links":{"context":1,"support":7},"ma_question":true,"named_voices":2,"passages":6,"sources":5,"sources_by_kind":{"commentary":4,"publication":1}},"title":"Adavosertib–olaparib: a clinician highlights toxicity behind the arm’s closure","title_holders":{"cited_claim_ids":["claim-3401402baf0c44466839","claim-4fcfc9ee484c1d7b67d4","claim-cba06addb3e43b256c28"],"clinicians":true,"holders":1,"speakers":2,"view":"reading"},"evidence_line":"7 statements from 2 speakers in 5 sources","holder_line":"1 of the 2 named speakers in this finding holds this view, a confirmed clinician"},{"cited_clinicians":1,"id":"F3","structure":{"claims":6,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":4,"views":1},"limitations":2,"links":{"context":0,"support":8},"ma_question":true,"named_voices":3,"passages":8,"sources":4,"sources_by_kind":{"commentary":3,"publication":1}},"title":"Non-HRR-mutated TNBC: a speaker asks if biomarkers could predict ATR–PARP benefit","title_holders":{"cited_claim_ids":["claim-6b5c93bfc0d8718e7312","claim-d0facfe76727a59f591e"],"clinicians":false,"holders":1,"speakers":3,"view":"reading"},"evidence_line":"6 statements from 3 speakers in 4 sources","holder_line":"1 of the 3 named speakers in this finding holds this view"},{"cited_clinicians":0,"id":"F4","structure":{"claims":2,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":1,"views":1},"limitations":2,"links":{"context":0,"support":2},"ma_question":false,"named_voices":2,"passages":2,"sources":2,"sources_by_kind":{"commentary":2}},"title":"VIOLETTE in 2017: a speaker looks forward to starting the trial","title_holders":{"cited_claim_ids":["claim-7bb90a8138eb21ac1ab7"],"clinicians":false,"holders":1,"speakers":2,"view":"reading"},"evidence_line":"2 statements from 2 speakers in 2 sources","holder_line":"1 of the 2 named speakers in this finding holds this view"}],"open_question":{"basis":"From finding F1 (12 statements from 2 speakers in 5 sources)","cited_claim_ids":["claim-01e1f75f58bc77ad877a","claim-2f5674d1e8d0b08786ef","claim-a7881637676c2357b211","claim-13f66949d36657b2d13e","claim-9bc7475b7e7fdd4ebc49","claim-dfc69d1a82b2f978eef0","claim-fe7ffeeb70f8f72baefb","claim-b063e37f529f615ba037","claim-ceef5b7bb0bab4bade8e","claim-f6448f7777a47e01765a","claim-24449506d7fd444bed0f","claim-810fbde91d754758142a"],"finding_ids":["F1"],"question":"In VIOLETTE’s second-/third-line, PARP inhibitor-naïve metastatic TNBC setting, what do clinicians need to see in PFS versus olaparib alone to consider response activity with ceralasertib plus olaparib clinically relevant, particularly in non-HRR-mutated disease?"},"sections":{"analysis":[{"id":"section-1","level":2,"title":"One X account questions whether ceralasertib–olaparib response activity without longer PFS is enough"},{"id":"section-2","level":2,"title":"X accounts describe the adavosertib–olaparib combination as too toxic to continue"},{"id":"section-3","level":2,"title":"Two X accounts ask whether better biomarkers could identify sensitivity to ATR plus PARP inhibition"},{"id":"section-4","level":2,"title":"One X account looked forward to starting VIOLETTE"},{"id":"section-5","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase2","trial_dimensions":[{"findings":[{"id":"F1","shared_claims":7},{"id":"F3","shared_claims":1}],"id":"T1","label":"Primary endpoint: Progression-free Survival Per Stratum (BICR)"},{"findings":[],"id":"T2","label":"Primary endpoint: Progression-free Survival Per Stratum (Sensitivity Analysis)"},{"findings":[{"id":"F1","shared_claims":5}],"id":"T3","label":"Secondary endpoints"},{"findings":[{"id":"F1","shared_claims":7},{"id":"F3","shared_claims":3}],"id":"T4","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":5},{"id":"F2","shared_claims":5},{"id":"F3","shared_claims":1}],"id":"T5","label":"The comparison"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":4},{"id":"F3","shared_claims":1}],"id":"T6","label":"Safety and tolerability"},{"findings":[{"id":"F2","shared_claims":4},{"id":"F4","shared_claims":1}],"id":"T7","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-11-19T17:38:25.022882Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-11-19T18:41:23Z","record_hash":"feaefadf878ac7771b708e7c6c44812f5ee210ffc3490ae05964a9e51c491d51","release_hash":"4737b1b26a08a1ca4647be9c3ade0740e7ade96387c7b158048bbdd6fc24ae17","report_id":"erudio-nct03330847","run_id":"a18f00a2-94d3-4cfb-8e62-e63d574bfef0","schema_version":"5.0","slug":"violette-nct03330847","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"A medical oncologist expresses disappointment with VIOLETTE, relaying no significant progression-free survival gain with ceralasertib–olaparib. An organization sees possible activity beyond HRR mutations but considers the clinical significance limited. Another medical oncologist links adavosertib–olaparib’s discontinuation to toxicity. A speaker suggests functional HRD or replication-stress biomarkers might refine selection; their predictive value is not established. These views establish neither routine-care preferences nor broader clinical agreement.","examples":[],"meta_description":"19 sources screened · 24 verified statements (4 from clinicians verified by NPI or staff page) from 7 sources · 4 findings. Updated Nov 19, 2026.","person_names_policy":"role_only"},"publication":{"approved_at":"2026-11-19T18:41:23Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":19},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","Not yet captured in this edition: a remark on planned olaparib combination comparisons and HR-pathway stratification in metastatic triple-negative breast cancer.","10 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: 42 sources about other trials or topics are not included; discussion that uses a name the trial shares with other things, without the trial's condition or setting, may be missing.","Relevant discussions that do not name VIOLETTE or use different spellings may be missing; the sources reviewed for this edition do not represent all public HCP commentary.","Publication-linked summaries, reposts and credited relays should not be counted as independent HCP evaluations or evidence of consensus.","Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.","ClinicalTrials.gov first posted results for the trial on 22 March 2022.","Exact regulatory-label information for the three study regimens was not available; this report does not assess labeled indications or dosing."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":0,"publication":1,"registry":0,"regulatory":0,"x_thread":6,"x_video":0,"youtube":0},"by_evidence_role":{"commentary":6,"context":1},"count":7,"evidence_window":{"end":"2026-10-07","start":"2017-12-07"},"retrieval_snapshot":"2026-11-19T15:08:10.323913Z","timeline":[{"count":2,"week":"2017-W49"},{"count":2,"week":"2022-W18"},{"count":1,"week":"2026-W40"},{"count":1,"week":"2026-W41"}],"undated_sources":1},"quote_policies":[{"id":"clinicaltrials:NCT03330847:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT03330847:results","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT03330847:context","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT03330847:protocol:1","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT03330847:sap:2","quote_policy":"short_quote_link_out"},{"id":"pubmed:34904813","quote_policy":"short_quote_link_out"},{"id":"pubmed:42765908","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-ryo5z53ggbjijxq7nd6ftqjx-3mwdpjt2gvs23","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1135498577457897472:2d8f260c-0e86-4c3f-81c9-5ad9d0757219","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1156285892098764801:87e36be9-2a4c-4688-9b9b-b2bb8dad4f32","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1521867281772515330:ee0e434e-0ac6-4921-b087-46bbd6d5f7b6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1521903077015572481:1b4378c5-75fa-4f1b-966c-2a01f19c909f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1523307868619153408:c5776dff-30aa-4ed3-a6cc-e2b4b14730c7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2102383521637478571:3e9053c8-fb84-4d52-a550-9f96329a4527","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2103452963427766589:6fe51009-14f8-4cf7-ab9f-a351323d7a48","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2104511445161624004:5feb12d3-cc72-4109-a242-f62655a2da18","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2105953437498425531:020ac0b5-2206-470a-bef5-bcc0826d76be","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2106034452761555189:55cea8ca-a83e-4ffc-8c3c-6e8afab33138","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2107838224718520637:c232c611-fc07-423e-9deb-19d66afda0b8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2108132051056537795:c4c8a8be-2235-47eb-baca-0659a28b3713","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2111078488996270538:41adbc56-3b58-4327-a0c6-e052aca44560","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2112265662592672010:77a50496-d993-4220-bf82-dfe5709d0720","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2112906878803951797:7ca0ea55-8978-40bf-bb68-0055068fa15b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113562628425388430:aa4d6079-8692-47c6-ae47-3840d532a07e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:938874597490950144:b7a88823-512e-4369-a452-a9fe7f2074d8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:938878410042077184:e7584d74-3255-4fbb-b33c-201d76033d15","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":1,"linkedin_post":0,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":18,"x_video":0,"youtube":0},"by_evidence_role":{"commentary":19},"count":19,"evidence_window":{"end":"2026-10-23","start":"2017-12-07"},"retrieval_snapshot":"2026-11-19T15:08:11.097015Z","timeline":[{"count":2,"week":"2017-W49"},{"count":1,"week":"2019-W23"},{"count":1,"week":"2019-W31"},{"count":3,"week":"2022-W18"},{"count":1,"week":"2022-W19"},{"count":3,"week":"2026-W39"},{"count":3,"week":"2026-W40"},{"count":2,"week":"2026-W41"},{"count":1,"week":"2026-W42"},{"count":3,"week":"2026-W43"}],"undated_sources":0},"statements_by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":0,"publication":6,"registry":0,"regulatory":0,"x_thread":18,"x_video":0,"youtube":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"congresses":{"reason":"No congress places this trial yet.","status":"none"},"drugs":[{"reason":"Unmapped registry intervention: olaparib continuous (28-day cycle) 300 mg bd.","status":"unmapped"},{"brand_names":{"reason":"No checked-in brand mapping.","status":"unmapped"},"label":"ceralasertib","slug":"ceralasertib"},{"brand_names":{"reason":"No checked-in brand mapping.","status":"unmapped"},"label":"adavosertib","slug":"adavosertib"}],"indications":[{"reason":"Unmapped registry condition: Metastatic Triple Negative Breast Cancer","status":"unmapped"},{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Breast cancer","slug":"breast-cancer"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"VIOLETTE","aliases":["VIOLETTE","D5336C00001","To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.","A Phase II, Open Label, Randomised, Multi-centre Study to Assess the Safety and Efficacy of Agents Targeting DNA Damage Repair in Combination With Olaparib Versus Olaparib Monotherapy in the Treatment of Metastatic Triple Negative Breast Cancer Patients Stratified by Alterations in Homologous Recombinant Repair (HRR)-Related Genes (Including BRCA1/2) (VIOLETTE)."],"brief_title":"To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Metastatic Triple Negative Breast Cancer"],"display_condition":"metastatic triple-negative breast cancer","display_interventions":[["ceralasertib","olaparib"],["adavosertib","olaparib"]],"enrollment":{"count":273,"type":"ACTUAL"},"interventions":[{"name":"Olaparib Continuous (28-Day cycle) 300 mg BD.","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Ceralasertib 160 mg OD + olaparib continuous 300 mg BD (28-day cycle).","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Adavosertib 150 mg BD + olaparib 200 mg BD (21-day cycle).","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"}],"nct_id":"NCT03330847","official_title":"A Phase II, Open Label, Randomised, Multi-centre Study to Assess the Safety and Efficacy of Agents Targeting DNA Damage Repair in Combination With Olaparib Versus Olaparib Monotherapy in the Treatment of Metastatic Triple Negative Breast Cancer Patients Stratified by Alterations in Homologous Recombinant Repair (HRR)-Related Genes (Including BRCA1/2) (VIOLETTE).","overall_status":"ACTIVE_NOT_RECRUITING","phase":["PHASE2"],"primary_completion_date":{"date":"2020-11-13","type":"ACTUAL"},"primary_endpoints":[{"description":"Progression-free survival was defined as time from randomization until the date of objective disease progression or death, regardless of whether the patient withdrew from randomized therapy or received another anti-cancer therapy prior to progression. Progression was determined by Blinded independent central review (BICR) using Response Evaluation Criteria In Solid Tumours Version (RECIST 1.1). Patients who had not progressed or died at the time of analysis were censored at the time of the latest date of assessment from their last evaluable RECIST assessment. If patients had no evaluable visits or baseline data, the patient was censored at Study Day 1, unless death occurred within 17 weeks i.e., death within 17 weeks was relative to randomization. Here, the study patient population was stratified as follows: Breast cancer susceptible gene mutation (BRCAm) patients; non BRCAm homologous recombination repair gene mutation (HRRm) patients; non HRRm patients.","measure":"Progression-free Survival Per Stratum (BICR)","timeFrame":"Until date of first documented progression or censoring date or date of death from any cause, whichever came first (assessed up to 32 months)"},{"description":"Progression-free survival was defined as time from randomization until the date of objective disease progression or death, regardless of whether the patient withdrew from randomized therapy or received another anti-cancer therapy prior to progression. Progression was determined by the site Investigator. Patients who had not progressed or died at the time of analysis were censored at the time of the latest date of assessment from their last evaluable RECIST 1.1 assessment. If patients had no evaluable visits or baseline data, the patient was censored at Study Day 1, unless death occurred within 17 weeks i.e., death within 17 weeks was relative to randomization. Here, the study patient population was stratified as follows: BRCAm patients; non BRCAm HRRm patients; non HRRm patients.","measure":"Progression-free Survival Per Stratum (Sensitivity Analysis)","timeFrame":"Until date of first documented progression or censoring date or date of death from any cause, whichever came first (assessed up to 32 months)"}],"registered_date":{"date":"2017-11-06","type":"ACTUAL"},"registry_last_updated":"2026-10-14","registry_url":"https://clinicaltrials.gov/study/NCT03330847","short_name":"VIOLETTE","short_name_basis":"canonical_name","sponsor":"AstraZeneca","start_date":{"date":"2018-03-07","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase2","study_ids":[{"id":"D5336C00001","type":"sponsor_study_id"},{"id":"2017-002361-22","type":"eudract_number"}],"study_type":"INTERVENTIONAL"}}}